iPSC-Derived Embryoid Bodies as Models of c- Met -Mutated Hereditary Papillary Renal Cell Carcinoma

Hereditary cancers with cancer-predisposing mutations represent unique models of human oncogenesis, as a driving oncogenic event is present in germline. Currently, there are no satisfactory models to study these malignancies. We report the generation of IPSC from the somatic cells of a patient with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of molecular sciences 2019-09, Vol.20 (19), p.4867
Hauptverfasser: Hwang, Jin Wook, Desterke, Christophe, Féraud, Olivier, Richard, Stephane, Ferlicot, Sophie, Verkarre, Virginie, Patard, Jean Jacques, Loisel-Duwattez, Julien, Foudi, Adlen, Griscelli, Frank, Bennaceur-Griscelli, Annelise, Turhan, Ali G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hereditary cancers with cancer-predisposing mutations represent unique models of human oncogenesis, as a driving oncogenic event is present in germline. Currently, there are no satisfactory models to study these malignancies. We report the generation of IPSC from the somatic cells of a patient with hereditary c- mutated papillary renal cell carcinoma (PRCC). From these cells we have generated spontaneous aggregates organizing in structures which expressed kidney markers such as PODXL and Six2. These structures expressed PRCC markers both in vitro and in vivo in NSG mice. Gene-expression profiling showed striking molecular similarities with signatures found in a large cohort of PRCC tumor samples. This analysis, applied to primary cancers with and without c- mutation, showed overexpression of the BHLHE40 and KDM4C only in the c- -mutated PRCC tumors, as predicted by c- -mutated embryoid bodies transcriptome. These data therefore represent the first proof of concept of "hereditary renal cancer in a dish" model using c- -mutated iPSC-derived embryoid bodies, opening new perspectives for discovery of novel predictive progression markers and for drug-screening for future precision-medicine strategies.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms20194867